Pricing updated 2019-07-23. Prices are subject to change without notice.
Glycoursodeoxycholic acid (GUDCA) is a glycine-conjugated form of the secondary bile acid ursodeoxycholic acid (UDCA; Item No. 15121).1,2 It has antioxidant effects in vitro in Barrett’s esophagus cells and primary cultured rat neurons.3,4 GUDCA reduces the levels of inflammatory cytokines and prevents cell death induced by unconjugated bilirubin in an astroglial cell model of neonatal hyperbilirubinemia.5 Oral administration of GUDCA (500 mg/kg per day) decreases the severity of symptoms and increases the amount of A. muciniphila, a bacterial species commonly decreased in patients with inflammatory bowel disease (IBD), in a mouse model of colitis.2
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Lefebvre, P., Cariou, B., Lien, F., et al. Role of bile acids and bile acid receptors in metabolic regulation Physiol. Rev. 89(1), 147-191 (2009).
Van den Bossche, L., Hindryckx, P., Devisscher, L., et al. Ursodeoxycholic acid and its taurine-
3. Goldman, A., Condon, A., Adler, E., et al. Protective effects of glycoursodeoxycholic acid in Barrett’s esophagus cells Dis. Esophagus 23(2), 83-93 (2010).
4. Brito, M.A., Lima, S., Fernandes, A., et al. Bilirubin injury to neurons: Contribution of oxidative stress and rescue by glycoursodeoxycholic acid Neurotoxicology 29(2), 259-269 (2008).
Fernandes, A., Vaz, A.R., Falcao, A.S., et al. Glycoursodeoxycholic acid and interleukin-